{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:55:17Z","timestamp":1778799317362,"version":"3.51.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Community Health"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s10900-021-01039-3","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T18:57:10Z","timestamp":1633892230000},"page":"211-225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional Study"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9953-7769","authenticated-orcid":false,"given":"Giancarlo","family":"Ripabelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Tamburro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicandro","family":"Buccieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Adesso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Caggiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Cannizzaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela Anna","family":"Di Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Mantuano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria Giovanna","family":"Montemitro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Natale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Rodio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela Lucia","family":"Sammarco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,9]]},"reference":[{"key":"1039_CR1","unstructured":"John Hopkins University & Medicine. Coronavirus Resource Center. COVID-19 Map. Retrieved August 3, 2021 from https:\/\/coronavirus.jhu.edu\/map.html"},{"issue":"5","key":"1039_CR2","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1016\/S1473-3099(20)30129-8","volume":"20","author":"A Wilder-Smith","year":"2020","unstructured":"Wilder-Smith, A., Chiew, C. J., & Lee, V. J. (2020). Can we contain the COVID-19 outbreak with the same measures as for SARS? Lancet Infectious Diseases, 20(5), e102-107. https:\/\/doi.org\/10.1016\/S1473-3099(20)30129-8","journal-title":"Lancet Infectious Diseases"},{"issue":"8","key":"1039_CR3","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.4014\/jmb.2006.06006","volume":"30","author":"KD Kim","year":"2020","unstructured":"Kim, K. D., Hwang, I., Ku, K. B., Lee, S., Kim, S. J., & Kim, C. (2020). Progress and challenges in the development of COVID-19 vaccines and current understanding of SARS-CoV-2-specific immune responses. Journal of Microbiology and Biotechnology, 30(8), 1109\u20131115. https:\/\/doi.org\/10.4014\/jmb.2006.06006","journal-title":"Journal of Microbiology and Biotechnology"},{"issue":"4","key":"1039_CR4","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3390\/vaccines8040739","volume":"8","author":"A Haque","year":"2020","unstructured":"Haque, A., & Pant, A. B. (2020). Efforts at COVID-19 vaccine development: Challenges and successes. Vaccines (Basel), 8(4), 739. https:\/\/doi.org\/10.3390\/vaccines8040739","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"1039_CR5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1080\/21645515.2020.1804777","volume":"17","author":"L Li","year":"2021","unstructured":"Li, L., Guo, P., Zhang, X., Yu, Z., Zhang, W., & Sun, H. (2021). SARS-CoV-2 vaccine candidates in rapid development. Human Vaccines & Immunotherapeutics, 17(3), 644\u2013653. https:\/\/doi.org\/10.1080\/21645515.2020.1804777","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"1039_CR6","unstructured":"COVID-19 Vaccine Tracker. Retrieved August 3, 2021 from https:\/\/covid19.trackvaccines.org\/vaccines\/"},{"issue":"8","key":"1039_CR7","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/jama.2021.0600","volume":"325","author":"T Shimabukuro","year":"2021","unstructured":"Shimabukuro, T., & Nair, N. (2021). Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA, 325(8), 780\u2013781. https:\/\/doi.org\/10.1001\/jama.2021.0600","journal-title":"JAMA"},{"key":"1039_CR8","unstructured":"European Medicines Agency. EMA recommends first COVID-19 vaccine for authorisation in the EU. News 21\/12\/2020. Retrieved July 15, 2021 from https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-first-covid-19-vaccine-authorisation-eu"},{"key":"1039_CR9","unstructured":"Italian Medicines Agency. BioNTech\/Pfizer vaccine authorised Answers to frequently asked questions on AIFA\u2019s website. Retrieved August 3, 2021 from https:\/\/www.aifa.gov.it\/en\/-\/autorizzato-il-vaccino-biontech-pfizer"},{"key":"1039_CR10","unstructured":"GEDI VISUAL. Retrieved August 4, 2021 from https:\/\/lab.gedidigital.it\/gedi-visual\/2021\/covid-19-vaccini-scopri-in-tempo-reale-quando-saremo-tutti-vaccinati\/"},{"issue":"2","key":"1039_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.23822\/EurAnnACI.1764-1489.86","volume":"51","author":"A Radice","year":"2019","unstructured":"Radice, A., Carli, G., Macchia, D., & Farsi, A. (2019). Allergic reactions after vaccination: Translating guidelines into clinical practice. European Annals of Allergy and Clinical Immunology, 51(2), 51\u201361. https:\/\/doi.org\/10.23822\/EurAnnACI.1764-1489.86","journal-title":"European Annals of Allergy and Clinical Immunology"},{"key":"1039_CR12","doi-asserted-by":"publisher","first-page":"579250","DOI":"10.3389\/fimmu.2020.579250","volume":"11","author":"KL Flanagan","year":"2020","unstructured":"Flanagan, K. L., Best, E., Crawford, N. W., et al. (2020). Progress and pitfalls in the quest for effective SARS-CoV-2 (COVID-19) vaccines. Frontiers in Immunology, 11, 579250. https:\/\/doi.org\/10.3389\/fimmu.2020.579250","journal-title":"Frontiers in Immunology"},{"key":"1039_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan, M. J., Lyke, K. E., Kitchin, N., et al. (2020). Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature, 586, 589\u2013593. https:\/\/doi.org\/10.1038\/s41586-020-2639-4","journal-title":"Nature"},{"issue":"20","key":"1039_CR14","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson, L. A., Anderson, E. J., Rouphael, N. G., et al. (2020). An mRNA vaccine against SARS-CoV-2\u2014Preliminary report. New England Journal of Medicine, 383(20), 1920\u20131931.","journal-title":"New England Journal of Medicine"},{"key":"1039_CR15","unstructured":"U.S. Food and Drug Administration. Pfizer-BioNTech COVID-19 Vaccine. Retrieved July 18, 2021 from https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/pfizer-biontech-covid-19-vaccine"},{"key":"1039_CR16","unstructured":"Italian Medicines Agency. Pharmacovigilance on COVID-19 vaccines. Retrieved July 18, 2021 from https:\/\/www.aifa.gov.it\/en\/farmacovigilanza-vaccini-covid-19"},{"issue":"9","key":"1039_CR17","doi-asserted-by":"publisher","first-page":"e548","DOI":"10.1111\/jdv.17343","volume":"35","author":"E Farinazzo","year":"2021","unstructured":"Farinazzo, E., Ponis, G., Zelin, E., et al. (2021). Cutaneous adverse reactions after m-RNA COVID-19 vaccine: Early reports from Northeast Italy. European Academy of Dermatology and Venereology, 35(9), e548\u2013e551. https:\/\/doi.org\/10.1111\/jdv.17343","journal-title":"European Academy of Dermatology and Venereology"},{"key":"1039_CR18","doi-asserted-by":"publisher","unstructured":"Lippi, G., Mattiuzzi, C., & Henry, B. Mild adverse reactions after COVID-19 vaccination: Updated analysis of Italian Medicines Agency data. Retrieved May 20, 2021 from https:\/\/ssrn.com\/abstract=3817988 or https:\/\/doi.org\/10.2139\/ssrn.3817988","DOI":"10.2139\/ssrn.3817988"},{"key":"1039_CR19","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P., Thomas, S. J., Kitchin, N., et al. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 383, 2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"1039_CR20","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","volume":"21","author":"C Menni","year":"2021","unstructured":"Menni, C., Klaser, K., May, A., et al. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study. Lancet Infectious Diseases, 21(7), 939\u2013949. https:\/\/doi.org\/10.1016\/S1473-3099(21)00224-3","journal-title":"Lancet Infectious Diseases"},{"key":"1039_CR21","unstructured":"European Medicines Agency. Comirnaty: EPAR\u2014Product information, last updated 20\/07\/2021. Retrieved August 20, 2021 from https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/comirnaty"},{"key":"1039_CR22","unstructured":"Italian Medicines Agency. Pharmacovigilance on COVID-19 vaccines. COVID-19 Vaccine Surveillance Report 7 27\/12\/2020\u201326\/07\/2021. Retrieved August 10, 2021 from https:\/\/www.aifa.gov.it\/farmacovigilanza-vaccini-covid-19"},{"issue":"8","key":"1039_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.15585\/mmwr.mm7008e3","volume":"70","author":"J Gee","year":"2021","unstructured":"Gee, J., Marquez, P., Su, J., et al. (2021). First month of COVID-19 vaccine safety monitoring\u2014United States, December 14, 2020\u2013January 13, 2021. Morbidity and Mortality Weekly Report, 70(8), 283\u2013288. https:\/\/doi.org\/10.15585\/mmwr.mm7008e3","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"51","key":"1039_CR24","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.1016\/j.vaccine.2013.09.066","volume":"31","author":"NA Halsey","year":"2013","unstructured":"Halsey, N. A., Griffioen, M., Dreskin, S. C., et al. (2013). Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: Reports to VAERS. Vaccine, 31(51), 6107\u20136112. https:\/\/doi.org\/10.1016\/j.vaccine.2013.09.066","journal-title":"Vaccine"},{"issue":"4","key":"1039_CR25","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.jaci.2018.12.1003","volume":"143","author":"JR Su","year":"2019","unstructured":"Su, J. R., Moro, P. L., Ng, C. S., Lewis, P. W., Said, M. A., & Cano, M. V. (2019). Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990\u20132016. Journal of Allergy and Clinical Immunology, 143(4), 1465\u20131473. https:\/\/doi.org\/10.1016\/j.jaci.2018.12.1003","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"4","key":"1039_CR26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3389\/fimmu.2018.02279","volume":"11","author":"A Bouman","year":"2005","unstructured":"Bouman, A., Heineman, M. J., & Faas, M. M. (2005). Sex hormones and the immune response in humans. Human Reproduction Update, 11(4), 411\u2013423. https:\/\/doi.org\/10.3389\/fimmu.2018.02279","journal-title":"Human Reproduction Update"},{"issue":"10","key":"1039_CR27","doi-asserted-by":"publisher","first-page":"e14605","DOI":"10.1111\/ijcp.14605","volume":"75","author":"S Cuschieri","year":"2021","unstructured":"Cuschieri, S., Borg, M., Agius, S., Souness, J., Brincat, A., & Grech, V. (2021). Adverse reactions to Pfizer-BioNTech vaccination of healthcare workers at Malta\u2019s state hospital. International Journal of Clinical Practice, 75(10), e14605. https:\/\/doi.org\/10.1111\/ijcp.14605","journal-title":"International Journal of Clinical Practice"},{"issue":"10","key":"1039_CR28","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein, S. L., & Flanagan, K. L. (2016). Sex differences in immune responses. Nature Reviews Immunology, 16(10), 626\u2013638. https:\/\/doi.org\/10.1038\/nri.2016.90","journal-title":"Nature Reviews Immunology"},{"issue":"3","key":"1039_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/acel.12326","volume":"14","author":"C Giefing-Kr\u00f6ll","year":"2015","unstructured":"Giefing-Kr\u00f6ll, C., Berger, P., Lepperdinger, G., & Grubeck-Loebenstein, B. (2015). How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell, 14(3), 309\u2013321. https:\/\/doi.org\/10.1111\/acel.12326","journal-title":"Aging Cell"},{"issue":"1","key":"1039_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/trstmh\/tru167","volume":"109","author":"SL Klein","year":"2015","unstructured":"Klein, S. L., Marriott, I., & Fish, E. N. (2015). Sex-based differences in immune function and responses to vaccination. Transactions of the Royal Society of Tropical Medicine and Hygiene, 109(1), 9\u201315. https:\/\/doi.org\/10.1093\/trstmh\/tru167","journal-title":"Transactions of the Royal Society of Tropical Medicine and Hygiene"},{"issue":"5","key":"1039_CR31","doi-asserted-by":"publisher","first-page":"e8094","DOI":"10.7759\/cureus.8094","volume":"12","author":"F Angum","year":"2020","unstructured":"Angum, F., Khan, T., Kaler, J., Siddiqui, L., & Hussain, A. (2020). The prevalence of autoimmune disorders in women: A narrative review. Cureus, 12(5), e8094. https:\/\/doi.org\/10.7759\/cureus.8094","journal-title":"Cureus"},{"issue":"1","key":"1039_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","volume":"11","author":"I Zucker","year":"2020","unstructured":"Zucker, I., & Prendergast, B. J. (2020). Sex differences in pharmacokinetics predict adverse drug reactions in women. Biology of Sex Differences, 11(1), 32. https:\/\/doi.org\/10.1186\/s13293-020-00308-5","journal-title":"Biology of Sex Differences"},{"key":"1039_CR33","doi-asserted-by":"publisher","first-page":"700014","DOI":"10.3389\/fmed.2021.700014","volume":"8","author":"X Xiong","year":"2021","unstructured":"Xiong, X., Yuan, J., Li, M., Jiang, B., & Lu, Z. K. (2021). Age and gender disparities in adverse events following COVID-19 vaccination: Real-world evidence based on big data for risk management. Frontiers in Medicine (Lausanne), 8, 700014. https:\/\/doi.org\/10.3389\/fmed.2021.700014","journal-title":"Frontiers in Medicine (Lausanne)"},{"issue":"4","key":"1039_CR34","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.coi.2013.07.009","volume":"25","author":"SS Shen-Orr","year":"2013","unstructured":"Shen-Orr, S. S., & Furman, D. (2013). Variability in the immune system: Of vaccine responses and immune states. Current Opinion in Immunology, 25(4), 542\u2013547. https:\/\/doi.org\/10.1016\/j.coi.2013.07.009","journal-title":"Current Opinion in Immunology"},{"issue":"5","key":"1039_CR35","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2020.03.017","volume":"145","author":"CE Gustafson","year":"2020","unstructured":"Gustafson, C. E., Kim, C., Weyand, C. M., & Goronzy, J. J. (2020). Influence of immune aging on vaccine responses. Journal of Allergy and Clinical Immunology, 145(5), 1309\u20131321. https:\/\/doi.org\/10.1016\/j.jaci.2020.03.017","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"1039_CR36","first-page":"ciab381","volume":"2017","author":"L M\u00fcller","year":"2021","unstructured":"M\u00fcller, L., Andr\u00e9e, M., Moskorz, W., et al. (2021). Age-dependent immune response to the Biontech\/Pfizer BNT162b2 COVID-19 vaccination. Clinical Infectious Diseases, 2017, ciab381.","journal-title":"Clinical Infectious Diseases"},{"key":"1039_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2021-002933","author":"A Ossato","year":"2021","unstructured":"Ossato, A., Tessari, R., Trabucchi, C., Zuppini, T., Realdon, N., & Marchesini, F. (2021). Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: A post-marketing Italian study conducted between 1 January and 28 February 2021. European Journal of Hospital Pharmacy. https:\/\/doi.org\/10.1136\/ejhpharm-2021-002933","journal-title":"European Journal of Hospital Pharmacy"},{"key":"1039_CR38","doi-asserted-by":"publisher","first-page":"100914","DOI":"10.1016\/j.eclinm.2021.100914","volume":"36","author":"A d\u2019Arminio Monforte","year":"2021","unstructured":"d\u2019Arminio Monforte, A., Tavelli, A., Perrone, P. M., et al. (2021). Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers. EClinicalMedicine, 36, 100914.","journal-title":"EClinicalMedicine"},{"key":"1039_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.05.035","author":"RK Raw","year":"2021","unstructured":"Raw, R. K., Kelly, C. A., Rees, J., Wroe, C., & Chadwick, D. R. (2021). Previous COVID-19 infection, but not Long-COVID, is associated with increased adverse events following BNT162b2\/Pfizer vaccination. Journal of Infection. https:\/\/doi.org\/10.1016\/j.jinf.2021.05.035","journal-title":"Journal of Infection"},{"key":"1039_CR40","doi-asserted-by":"publisher","first-page":"n308","DOI":"10.1136\/bmj.n308","volume":"372","author":"J Wise","year":"2021","unstructured":"Wise, J. (2021). Covid-19: People who have had infection might only need one dose of mRNA vaccine. BMJ, 372, n308. https:\/\/doi.org\/10.1136\/bmj.n308","journal-title":"BMJ"},{"issue":"10279","key":"1039_CR41","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S0140-6736(21)00501-8","volume":"397","author":"C Manisty","year":"2021","unstructured":"Manisty, C., Otter, D., Treibel, T. A., et al. (2021). Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet, 397(10279), 1057\u20131058. https:\/\/doi.org\/10.1016\/S0140-6736(21)00501-8","journal-title":"Lancet"},{"issue":"11","key":"1039_CR42","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1136\/archdischild-2015-310282","volume":"102","author":"AJ Pollard","year":"2017","unstructured":"Pollard, A. J., Finn, A., & Curtis, N. (2017). Non-specific effects of vaccines: Plausible and potentially important, but implications uncertain. Archives of Disease in Childhood, 102(11), 1077\u20131081. https:\/\/doi.org\/10.1136\/archdischild-2015-310282","journal-title":"Archives of Disease in Childhood"},{"issue":"2","key":"1039_CR43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","volume":"21","author":"AJ Pollard","year":"2021","unstructured":"Pollard, A. J., & Bijker, E. M. (2021). A guide to vaccinology: From basic principles to new developments. Nature Reviews Immunology, 21(2), 83\u2013100. https:\/\/doi.org\/10.1038\/s41577-020-00479-7","journal-title":"Nature Reviews Immunology"},{"issue":"4","key":"1039_CR44","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/S2589-7500(20)30026-1","volume":"2","author":"K Sun","year":"2020","unstructured":"Sun, K., Chen, J., & Viboud, C. (2020). Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: A population-level observational study. Lancet Digital Health, 2(4), e201-208. https:\/\/doi.org\/10.1016\/S2589-7500(20)30026-1","journal-title":"Lancet Digital Health"},{"issue":"1","key":"1039_CR45","first-page":"e35","volume":"8","author":"A Emami","year":"2020","unstructured":"Emami, A., Javanmardi, F., Pirbonyeh, N., & Akbari, A. (2020). Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Archives of Academic Emergency Medicine, 8(1), e35.","journal-title":"Archives of Academic Emergency Medicine"},{"key":"1039_CR46","unstructured":"Italian Medicines Agency. Vaccination with Pfizer (Comirnaty) COVID-19 mRNA BNT162b2 vaccine AIFA FAQs. Retrieved August 20, 2021 from https:\/\/www.aifa.gov.it"},{"key":"1039_CR47","unstructured":"Epicentro, Istituto Superiore di Sanit\u00e0. Caratteristiche dei pazienti deceduti positivi all\u2019infezione da SARS-CoV-2 in Italia, updated on 21 July 2021. Retrieved August 20, 2021 from https:\/\/www.epicentro.iss.it\/coronavirus\/sars-cov-2-decessi-italia#4"},{"issue":"21","key":"1039_CR48","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1001\/jama.2021.5374","volume":"32","author":"J Chapin-Bardales","year":"2021","unstructured":"Chapin-Bardales, J., Gee, J., & Myers, T. (2021). Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA, 32(21), 2201\u20132202. https:\/\/doi.org\/10.1001\/jama.2021.5374","journal-title":"JAMA"},{"key":"1039_CR49","unstructured":"Centers for Diseases Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. Retrieved August 19, 2021 from https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html"},{"key":"1039_CR50","unstructured":"Looking Glass Optical Eye Care Center, updated on 26 April 2021. Retrieved August 19, 2021 from https:\/\/www.lookingglassoptical.com\/covid-19-vaccine-affect-your-vision\/"},{"key":"1039_CR51","unstructured":"Abc news. Health officials track safety as COVID-19 vaccines roll out. Retrieved August 20, 2021 from https:\/\/abcnews.go.com\/amp\/Health\/wireStory\/health-officials-track-safety-covid-19-vaccines-roll-74767373"},{"issue":"6","key":"1039_CR52","first-page":"37","volume":"103","author":"V Selvaraj","year":"2020","unstructured":"Selvaraj, V., Sacchetti, D., Finn, A., & Dapaah-Afriyie, K. (2020). Acute Vision Loss in a Patient with COVID-19. Rhode Island Medical Journal (2013), 103(6), 37\u201338.","journal-title":"Rhode Island Medical Journal (2013)"},{"issue":"3","key":"1039_CR53","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/WNO.0000000000001039","volume":"40","author":"DG Cyr","year":"2020","unstructured":"Cyr, D. G., Vicidomini, C. M., Siu, N. Y., & Elmann, S. E. (2020). Severe bilateral vision loss in 2 patients with coronavirus disease 2019. Journal of Neuro-Ophthalmology, 40(3), 403\u2013405.","journal-title":"Journal of Neuro-Ophthalmology"},{"key":"1039_CR54","unstructured":"The conversation. COVID-19 could cause male infertility and sexual dysfunction\u2014But vaccines do not, updated on 26 July 2021. Retrieved August 20, 2021 from https:\/\/theconversation.com\/covid-19-could-cause-male-infertility-and-sexual-dysfunction-but-vaccines-do-not-164139"},{"key":"1039_CR55","unstructured":"Factcheck.org. Research rebuts claims linking COVID-19 vaccines to male infertility, updated on 17 June 2021. Retrieved August 20, 2021 from https:\/\/www.factcheck.org\/2021\/06\/scicheck-research-rebuts-baseless-claims-linking-covid-19-vaccines-to-male-infertility\/"},{"issue":"3","key":"1039_CR56","doi-asserted-by":"publisher","first-page":"466","DOI":"10.5534\/wjmh.210055","volume":"39","author":"E Kresch","year":"2021","unstructured":"Kresch, E., Achua, J., Saltzman, R., et al. (2021). COVID-19 endothelial dysfunction can cause erectile dysfunction: Histopathological, immunohistochemical, and ultrastructural study of the human penis. World Journal of Men\u2019s Health, 39(3), 466\u2013469. https:\/\/doi.org\/10.5534\/wjmh.210055","journal-title":"World Journal of Men\u2019s Health"},{"issue":"1","key":"1039_CR57","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5534\/wjmh.200170","volume":"39","author":"JK Achua","year":"2021","unstructured":"Achua, J. K., Chu, K. Y., Ibrahim, E., et al. (2021). Histopathology and ultrastructural findings of fatal COVID-19 infections on testis. World Journal of Men\u2019s Health, 39(1), 65\u201374. https:\/\/doi.org\/10.5534\/wjmh.200170","journal-title":"World Journal of Men\u2019s Health"},{"issue":"6","key":"1039_CR58","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/HYPERTENSIONAHA.121.17316","volume":"77","author":"S Meylan","year":"2021","unstructured":"Meylan, S., Livio, F., Foerster, M., et al. (2021). Stage III hypertension in patients after mRNA-based sars-cov-2 vaccination. Hypertension, 77(6), e56-57. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.121.17316","journal-title":"Hypertension"},{"key":"1039_CR59","unstructured":"American Academy of Allergy Asthma & Immunology. Hypertension after mRNA COVID-19 vaccine. Retrieved August 20, 2021 from https:\/\/www.aaaai.org\/allergist-resources\/ask-the-expert\/answers\/2021\/hypertension"}],"container-title":["Journal of Community Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10900-021-01039-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10900-021-01039-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10900-021-01039-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T06:14:51Z","timestamp":1647670491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10900-021-01039-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,9]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1039"],"URL":"https:\/\/doi.org\/10.1007\/s10900-021-01039-3","relation":{},"ISSN":["0094-5145","1573-3610"],"issn-type":[{"value":"0094-5145","type":"print"},{"value":"1573-3610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,9]]},"assertion":[{"value":"1 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All participants provided informed consent prior to study participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"No individual\u2019s data or image are available.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"This study did not require ethics approval as no experimental procedure was applied, and data were anonymously collected from participants who previously signed an informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}